GynSight

GynSight application is targeted to patients who are participating in a Randomized Control Trial of BRAVE - BiomarkeR and App to Validate Endometriosis pain (BRAVE) study. BRAVE involves researchers from entities across department of defense (ARPA-H), and peer medical institutes to identify bio-markers related to pain and develop an objective measure of pain. The study is approved under IRB ID #: 202501007
GynSight mobile app enables Ecological Momentary Assessment of patients where patients app gathers pain characteristics via direct and in-direct assessment. For example, a longitudinal assessment of health markers such as heart rate across daily cycle, responsiveness to simple tasks via games and indirect assessments of mood and basic health via clinically designed questionnaire. Patients under study signed a consent for participation outside GynSight, following which patients are invited to participate and use the Mobile App.
Data captured via GynSight is plotted against bio-markers (blood samples, collected at physician's office on a regular basis) to analyze signs of behavioral impact during pain.